BiotechTube
Home/Atonco/Jacques BARBET
JB

Jacques BARBET

Chief Scientific Officer

Atonco

Therapeutic Areas

Oncology

Atonco Pipeline

DrugIndicationPhase
Astatine-211-labeled anti-CAIX antibody (girentuximab)Non-Muscle Invasive Bladder Cancer (NMIBC), refractory to BCG/chemotherapyPre-clinical

Leadership Team at Atonco

SF
Sylvain FANIER
CEO
JC
Jean-François CHATAL
Chief Medical Officer
A(
Alexandra (GITEAU) PAILLARD
COO
CM
Clément MAYEUR
Chief Financial Officer
AR
Adrien REYMOND
Business Development Director
DB
Denis BILODEAU
Clinical Research Developer
View full Atonco profile